Glaukos Corp GKOS 深 沪
等待开盘 02-09 09:30:00 美东时间
112.52
-1.000
-0.88%
华盛通- 最 高114.975
- 今 开114.37
- 成交量 95.16万股
- 最 低 110.65
- 昨 收 113.52
- 总市值 64.63亿
- 52周最高 161.78
- 市盈率 静 --
- 换手率 1.66%
- 52周最低 73.16
- 委 比 -81.82%
- 总股本 5743.47万
- 历史最高 163.71
- 量 比 1.36
- 振 幅 3.81%
- 历史最低 14.25
- 每 手 1
- 风险率 16.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
BUZZ-U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
BUZZ-U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 crossed the 7,000 mark for the first time on Wednesday and the N
01-28 23:48
BUZZ-U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker International
BUZZ-U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 was poised to open close to the 7,000
01-28 22:12
BUZZ-Glaukos rises as FDA allows repeat use of glaucoma implant
BUZZ-Glaukos rises as FDA allows repeat use of glaucoma implant ** Shares of medtech firm Glaukos GKOS.N rise 4% to $122.94 premarket ** Co says U.S. FDA now allows doctors to re-administer its "iDose TR" implant, which steadily releases glaucoma medicine to lower eye pressure ** Glaucoma is a dise
01-28 21:36
BRIEF-Glaukos Announces US FDA Approval Of NDA Supplement Allowing For Re-Administration Of Idose® Tr
BRIEF-Glaukos Announces US FDA Approval Of NDA Supplement Allowing For Re-Administration Of Idose® Tr Jan 28 (Reuters) - Glaukos Corp GKOS.N : GLAUKOS ANNOUNCES US FDA APPROVAL OF NDA SUPPLEMENT ALLOWING FOR RE-ADMINISTRATION OF IDOSE® TR GLAUKOS CORP - IDOSE TR SHOWS FAVORABLE LONG-TERM CORNEAL SAF
01-28 20:04
FDA Approves Glaukos Labeling Supplement Allowing iDose TR Re-Administration
FDA Approves Glaukos Labeling Supplement Allowing iDose TR Re-Administration Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement to the New Drug Application (NDA) for iDose® TR, allowing for the re-administration of the product using a re
01-28 20:01
Glaukos President and COO Joseph E. Gilliam Reports Disposal of Common Shares
Glaukos President and COO Joseph E. Gilliam Reports Disposal of Common Shares Joseph E. Gilliam, President & COO of Glaukos Corporation, reported a disposal of common shares of Glaukos Corporation. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Pub
01-24 09:43
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Stifel Maintains Buy on Glaukos, Raises Price Target to $160
Stifel analyst Thomas Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $115 to $160.
01-22 20:58
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies Jan 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cencora, Crocs and Teledyne Technologies, on Thursday. HIGHLIGHTS * Cencora COR.N : Jefferies raises to b
01-22 15:17
